Patents Examined by Paul V. Ward
  • Compounds and compositions for the treatment of neurodegenerative and inflammatory diseases
    Patent number: 11541023
    Abstract: The invention relates to compounds exhibiting kallikrein inhibitory activity, and to compositions comprising at least one of these compounds for use in the treatment of diseases or disorders in which kallikrein activity is dysregulated, particularly neurodegenerative and inflammatory diseases.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: January 3, 2023
    Assignees: SARBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS, INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE, UNIVERSITÉ DE MONTPELLIER, ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER
    Inventors: Chahrazade El Amri, Feryel Soualmia, Nicolas Masurier, Sabrina Aït Amiri, Brahim Nait Oumesmar, Cyrille Deboux
  • Method of preparing a composition comprising ferulic acid
    Patent number: 11541025
    Abstract: The present invention relates to a method of preparing a composition comprising ferulic acid. An aspect of the invention is a composition comprising hydrolysed wheat bran for use in the treatment or prevention of metabolic disease.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: January 3, 2023
    Assignee: Societe des Produits Nestle S.A.
    Inventor: Rachid Bel-Rhlid
  • Histone demethylase inhibitors
    Patent number: 11535616
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
    Type: Grant
    Filed: September 21, 2020
    Date of Patent: December 27, 2022
    Assignee: CELGENE QUANTICEL RESEARCH, INC
    Inventors: Amogh Boloor, Toufike Kanouni, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace
  • Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
    Patent number: 11535634
    Abstract: The present disclosure provides, e.g., compounds, compositions, kits, methods of synthesis, and methods of use, involving epipolythiodiketopiperazines and polythiodiketopiperazines.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: December 27, 2022
    Assignee: Massachusetts Institute of Technology
    Inventors: Mohammad Movassaghi, Chase Robert Olsson, Tony Z. Scott, Jaime Cheah, Joshua Nathaniel Payette
  • Compositions and methods for treating infections
    Patent number: 11530198
    Abstract: The invention relates to inhibitors of dihydrofolate reductase and pharmaceutical preparations thereof. The invention further relates to methods of treatment of parasitic infections, such as T. gondii, T. cruzi, P. falciparum, T. brucei, or L. major infections, using the novel inhibitors of the invention.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: December 20, 2022
    Assignee: Vyera Pharmaceuticals, LLC
    Inventors: Stephen B. Thomas, Allen T. Hopper, Matthew Welsch
  • Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators
    Patent number: 11530210
    Abstract: Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: December 20, 2022
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Afton Hiscox, Brice Stenne, Christa Chrovian, Christine Gelin, Andrew Samant, Michael A. Letavic, Curt Dvorak
  • Alkyne substituted quinazoline compound and methods of use
    Patent number: 11524956
    Abstract: The invention provides alkyne substituted quinazoline compounds, such as compounds of the formula (I), which are irreversible ErbB kinase inhibitors. The compounds are useful in the treatment of diseases and disorders where ErbB kinase activity is implicated such as a hyperproliferative disorder (e.g., cancer).
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: December 13, 2022
    Assignee: Newgen Therapeutics, Inc.
    Inventors: Wang Shen, Aimin Zhang, Jack Maung, Xiaoling Zheng
  • Heterocyclic compounds for the treatment of neurological and psychological disorders
    Patent number: 11518745
    Abstract: Lactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: December 6, 2022
    Assignee: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Julius F. Remenar, Laura Cook Blumberg, Tarek A. Zeidan
  • Guanidyl-containing P2Y12 receptor antagonist and preparation method and application thereof
    Patent number: 11512056
    Abstract: A P2Y12 receptor antagonist containing a guanidyl, and a preparation method and the use thereof. In particular, the present disclosure provides a pyridazinone-guanidine compound that is a compound of structural formula (I), or a stereoisomer of the above-mentioned compound, a pro-drug thereof, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof. Such a compound has multiple pharmacological activities, especially has an inhibitory effect on platelet aggregation, and can be used for preparing an anti-platelet aggregation pharmaceutical composition.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: November 29, 2022
    Assignee: Anhui New Star Pharmaceutical Development Co., Ltd
    Inventors: Xiaoxiang Li, Ziao Xu, Degang Li, Yumei Xu, Yonghai Zhao, Genling Jiang
  • Heteroaryl compound having drug activity
    Patent number: 11512085
    Abstract: The present invention provides a class of novel compounds having Btk selective inhibitory activity, better metabolic stability and the like.
    Type: Grant
    Filed: December 22, 2019
    Date of Patent: November 29, 2022
    Assignee: SHANGHAI DUDE MEDICAL TECHNOLOGY CO., LTD
    Inventors: Xin Liu, Zhedong Yuan, Rui Kong, Shan Chen
  • Dihydropyridines for the treatment of cognitive impairment or traumatic brain injury
    Patent number: 11512052
    Abstract: A genus of dihydropyridine chemical modulators of synaptojanin is disclosed. These modulators are selective inhibitors of synaptojanin 1 and may be used to treat cognitive impairment or traumatic brain injury, including promoting regeneration in cases of traumatic brain injury, or for treating neurodegenerative disorders.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: November 29, 2022
    Assignees: Icahn School of Medicine at Mount Sinai, The United States Government as Represented by the Department of Veterans Affairs
    Inventors: Michael Ohlmeyer, Dongming Cai
  • Inhibitors of fibroblast activation protein
    Patent number: 11504364
    Abstract: Compounds and compositions for modulating fibroblast activation protein (FAP) are described. The compounds and compositions may find use as therapeutic agents for the treatment of diseases, including hyperproliferative diseases.
    Type: Grant
    Filed: December 21, 2019
    Date of Patent: November 22, 2022
    Assignee: PRAXIS BIOTECH LLC
    Inventors: Brahmam Pujala, Dayanand Panpatil, Sebastian Bernales, Sebastian Belmar, Gonzalo Andrés Ureta Díaz
  • Theramutein modulators
    Patent number: 11504377
    Abstract: This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.
    Type: Grant
    Filed: September 30, 2020
    Date of Patent: November 22, 2022
    Assignee: HMI MEDICAL INNOVATIONS, LLC
    Inventor: Gerard M. Housey
  • Anthelmintic quinoline-3-carboxamide derivatives
    Patent number: 11505545
    Abstract: The present invention covers new quinoline compounds of general formula (I): in which A, R1, R2, R3, R4, R5, R6, and Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: November 22, 2022
    Assignee: Bayer Animal Health GmbH
    Inventors: Walter Hübsch, Johannes Köbberling, Adeline Köhler, Hans-Georg Schwarz, Daniel Kulke, Claudia Welz, Thomas Ilg, Kirsten Börngen, Wei Zhuang, Nils Griebnow, Claudia Böhm, Niels Lindner, Maike Hink, Ulrich Görgens
  • Use of tapinarof for the treatment of atopic dermatitis
    Patent number: 11497718
    Abstract: Topical compositions and methods for using topical compositions comprising tapinarof to treat mild to moderate atopic dermatitis are described herein. Also described are clinical endpoints for treatment of subjects diagnosed with mild to moderate atopic dermatitis, wherein about 5% to about 35% of body surface area was affected, and Investigator Global Assessment (IGA) score was greater than or equal to 3.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: November 15, 2022
    Assignee: DERMAVANT SCIENCES GMBH
    Inventors: John E. Kraus, James Lee
  • Crystalline FGFR4 inhibitor compound and uses thereof
    Patent number: 11498916
    Abstract: A number of crystalline forms of N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-y1)phenyl)acrylamide are provided. These include a crystalline free base form, a crystalline monohydrochloride salt form, a crystalline dihydrochloride salt form, and a crystalline ethanesulfonate salt form. Methods of making and using crystalline compounds are also provided.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: November 15, 2022
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: George Moniz, Kristen Sanders, Arani Chanda, Kenshi Yoshida, Ming-Hong Hao, Dominic Reynolds, Sudeep Prajapati, Anand Selvaraj, Takashi Satoh, John Wang
  • Compositions and methods for treating lung injuries associated with SARS-CoV-2 infections
    Patent number: 11497747
    Abstract: The present invention provides methods and compositions for treating and preventing lung injuries due to or associated with coronavirus infections that cause Severe Acute Respiratory Syndrome, including COVID-19. More specifically the present invention provides methods for treating or preventing the lung injuries associated with SARS-CoV-2 infections, such as acute lung injury (ALI), lung fibrosis, and acute respiratory distress syndrome (ARDS). The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising a protein kinase inhibitor compound having MAP3K2/MAP3K3 inhibition activity, such as pazopanib or nintedanib, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, to a patient in need thereof. The present invention also provides devices for administering the compositions.
    Type: Grant
    Filed: March 17, 2022
    Date of Patent: November 15, 2022
    Assignees: Qx Therapeutics Inc., Yale University
    Inventors: Dianqing Wu, Ho Yin Lo
  • Treatment for obesity
    Patent number: 11497725
    Abstract: The present invention relates to a method for treating or preventing obesity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds. The invention further relates to methods for reducing body weight and/or reducing food intake in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds.
    Type: Grant
    Filed: September 22, 2020
    Date of Patent: November 15, 2022
    Assignees: Axsome Malta Ltd., SK Biopharmaceuticals Co., Ltd.
    Inventors: Moise A. Khayrallah, Gary Bream, Stephen E. Butts
  • Barbituric acid derivatives, their preparation and use thereof as leukocyte transmigration inhibitors and for treating inflammatory diseases, autoimmune diseases and cancer
    Patent number: 11492333
    Abstract: Provided herein are novel barbituric acid derivatives, their synthesis and use thereof in blocking leukocyte transmigration. The novel barbituric acid derivatives are useful for the treatment of disorders associated with leukocyte transmigration, such as for example inflammatory diseases and disorders, autoimmune diseases and disorders, and cancers.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: November 8, 2022
    Assignees: BAR-ILAN UNIVERSITY, UNIVERSITY OF GENEVA, GENEVA UNIVERSITY HOSPITALS
    Inventors: Arie Lev Gruzman, Paul Bradfield, Tamar Getter, Beat Imhof, Thomas Matthes, Hanoch Senderowitz
  • Theramutein modulators
    Patent number: 11491164
    Abstract: This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.
    Type: Grant
    Filed: September 30, 2020
    Date of Patent: November 8, 2022
    Assignee: HMI MEDICAL INNOVATIONS, LLC
    Inventor: Gerard M. Housey